On August 20, DUALITYBIO-B rose 5.56% in regular trading, trading at 195.4 HKD/share, with turnover of approximately 42.40 million HKD. The rally was driven by UBS initiating coverage with a \"Buy\" rating and a target price of 320 HKD, implying approximately 65% upside from current levels.

UBS noted that the current share price corresponds to only 0.7x risk-adjusted peak sales ratio, significantly below the peer median of 1.6x, suggesting an attractive valuation. The bank identified DB-1311 as the key value driver, projecting peak sales of RMB 38.3 billion, above market consensus of RMB 28.6 billion. UBS forecasts total revenue to grow from RMB 1.8 billion to RMB 22.8 billion by 2035, with EBITDA turning positive by 2030. Additionally, multiple brokerages including China Merchants Securities, Soochow Securities, and China Galaxy Securities have recently initiated coverage with positive ratings.

The broader Biotechnology sector showed notable strength, with EVEREST MED up 48.24%, CANSINOBIO up 46.96%, AKESO up 7.78%, INNOVENT BIO up 4.94%, and BEONE MEDICINES up 4.38%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)